ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gilead Adds Manufacturing

by Rick Mullin
June 8, 2015 | APPEARED IN VOLUME 93, ISSUE 23

Gilead Sciences says its Canadian subsidiary, Gilead Alberta, will invest $100 million in a new active pharmaceutical ingredient (API) manufacturing plant at its Edmonton facility, where it officially opened the first of two new laboratory buildings late last month. The additional laboratory space will accommodate 170 jobs. The new plant will provide APIs for clinical research in a variety of areas, including hepatitis C, HIV/AIDS, and oncology.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment